By: P. Vlummens MD
Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment modalities, alongside optimization of those already available, boldly continues. Each year, the ASH congress offers us the opportunity to learn about the latest developments in the MM field. This text aims to provide a brief summary of some of the latest insights presented at ASH this year.
(BELG J HEMATOL 2017;8(1):3–7)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
